{
  "scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial of Landiolol for Tachyarrhythmias Management"
      },
      "Trial_Design": {
        "score": 2,
        "evidence": "randomised using a computer-generated sequence with allocation concealment via sealed envelopes"
      },
      "Participants": {
        "score": 2,
        "evidence": "conducted in Japan, with participants recruited from cardiac and non-cardiac surgery settings. Eligibility criteria included patients with intraoperative tachyarrhythmias"
      },
      "Intervention": {
        "score": 2,
        "evidence": "Participants received either landiolol or a comparator \u03b2-blocker, esmolol, for heart rate control"
      },
      "Objective": {
        "score": 1,
        "evidence": "To evaluate the efficacy and safety of landiolol compared to esmolol in controlling heart rate"
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was heart rate control within 24 hours post-intervention"
      },
      "Randomisation_Allocation": {
        "score": 2,
        "evidence": "randomised using a computer-generated sequence with allocation concealment via sealed envelopes"
      },
      "Blinding": {
        "score": 3,
        "evidence": "Blinding was applied to outcome assessors, patients, and clinicians"
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "A total of 200 participants were randomised: 100 to the landiolol group and 100 to the esmolol group"
      },
      "Number_Analysed": {
        "score": 2,
        "evidence": "Analysis was conducted on 98 participants in the landiolol group and 97 in the esmolol group using an intention-to-treat approach"
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "Landiolol demonstrated superior heart rate control (mean difference = 5.2 bpm, 95% CI 3.1 to 7.3; p = 0.01)"
      },
      "Harms": {
        "score": 1,
        "evidence": "Adverse events were mild, with 3% in the landiolol group and 1% in the esmolol group experiencing mild gastrointestinal side-effects"
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "The trial was registered under number XYZ123"
      },
      "Funding": {
        "score": 1,
        "evidence": "The study was funded by ABC Pharmaceuticals"
      }
    },
    "total_score": 24,
    "max_score": 25
  },
  "model": "gpt-4o"
}